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ABSTRACT 
Thioredoxin systems, comprising Trx, TrxR and NADPH, are one of the major 
disulfide reductase systems, which is crucial in maintaining cellular redox balance in 
mammalian cells. TrxR is a selenoprotein with a Sec residue in its C-terminal active 
site. The low pKa value and the easily accessible property of the Sec residue make TrxR 
a target of many electrophilic compounds, including some clinically approved drugs. 
TrxR exert most of its cellular function by reducing Trx. Through the substrates of Trx, 
or its interacting proteins, Trx plays important roles in DNA synthesis, cellular defense 
against oxidative stress, regulation of transcription factors and cell death pathways.  
 
There are two distinct Trx systems in mammalian cells, Trx1 system located in cytosol 
and Trx2 system located in mitochondria. In Paper I we found that treatment with 
brilliant green (BG) can cause a dramatic decrease of Trx2 in the mitochondria and 
subsequent cell death. The natural amount of Trx2 in Hela cells are much higher 
compared to that in fibroblast cells. Down-regulation of the amount of Trx2 by using an 
siRNA method in both cell lines can greatly sensitize Hela cells towards BG toxicity, 
but not fibroblast cells, suggesting the importance of Trx2 for some cancer cells.  
 
Different from Trx2, which only have two Cys residues in the active site; Trx1 has 
three additional Cys residues, Cys62, Cys69 and Cys73. Previous studies about the 
function of Trx1 are mainly focused on the active site cysteines. However, 
accumulating evidence showed that the three so called structural Cys residues also play 
important roles in regulating Trx1´s activities and functions. In paper II and IV, we 
focused on studying the impact of the second disulfide (Cys62-Cys69) on Trx1 activity. 
We show that Trx1 with two disulfides can be found in cells under high oxidative 
stress, and although it is not a substrate of TrxR, but it can be reduced by the 
glutaredoxin (Grx) system at the expense of GSH.  In addition the formation of the 
second disulfide or only the disulfide between Cys62 and Cys69 disturbed the ability of 
Trx1 to reduce oxidized Prx1, and sensitized SH-SH5Y cells towards arsenic 
compounds inducing cell death.  
 
In Paper III we characterized that GSH plus Grx2 can be a backup of TrxR and can 
reduce both Trx1 and Trx2 when TrxR was inhibited. Overexpression of Grx2 in Hela 
cells can protect cells from cell death induced by the inhibitors of TrxR.  
 
Apart from Trxs, we also explored the role of TrxR as a target of the clinically applied 
anti-cancer drug mitomycin C and mercury. In paper V, we proposed that targeting 
TrxR as a new mechanism of mitomycin C´s action. In Paper VI, TrxR was shown to 
be a target of mercury, and selenium can reactivated the TrxR treated with mercury by 
a substitution mechanism.  
 
In summary, in the thesis we stressed the role of Trx and TrxR in the cell death induced 
by the toxic compounds which are targeting the Trx system.  
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1 INTRODUCTION 
 
1.1 CELL DEATH PATHWAYS 
Cells are considered to be dead after they pass the first irreversible phase or the so 
called "point-of-no-return"
1
. There are two major pathways of cell death to be 
clarified: apoptosis and necrosis. These two types of cell death pathways are 
classified according to the difference in the cell’s morphological and biochemical 
properties. Generally from the morphological point of view, apoptotic cells maintain 
a functioning membrane throughout the whole process, and the cell shrinks by losing 
water; necrotic cells, lose their membrane integrity at a very early stage and then the 
cell swells due to the influx of water, sodium and calcium
1
. 
Apoptosis or programmed cell death needs stimulating signals from either inside or 
outside of the cells. When the signals are from inside of the cells (the intrinsic 
pathway), mitochondria play an important role in this kind of apoptosis. The intrinsic 
signal, which can be DNA damage, reactive oxygen species (ROS), as well as 
growth-factor depletion, first reaches mitochondria. Then, the proapoptotic members 
of the Bcl-2 family proteins are activated and start to form pores in the mitochondrial 
outer membrane
2
, which then can facilitate the release of proapoptotic proteins from 
mitochondria, such as cytochrome c and apoptosis inducing factor (AIF). Cytochrome 
c can promote the formation of the apoptosome, and subsequently activate the 
caspase pathway
3
.  
The apoptotic signal can also come from outside of the cells, in a manner called 
extrinsic receptor mediated pathway. The receptors which can receive such stimuli 
are belonging to the tumor necrosis factor (TNF) receptor superfamily
4
. Upon the 
stimuli, a complex called Death Inducing Signalling Complex (DISC) is formed in 
the membrane and subsequently actives caspase-8
5,6
. the activated caspase-8 can 
either directly active caspase-3 or activate Bid, a proapoptotic member of Bcl-2 
family, and initiate the mitochondrial signalling pathways
7
. 
Apoptosis is considered as a natural process which could occur in both physiological 
and pathological conditions. It is also a part of the normal maintenance process for 
the multicellular lives to remove “unhealthy” cells, for example, cells undergoing 
carcinogenesis
8
.  In contrast of apoptosis, necrosis is considered to be an 
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unprogrammed, energy independent and toxic process of cell death. It is worth to 
mention, new findings suggest that necrosis, even not the whole process, is also 
regulated in some way
9,10
.  
 
1.2 REACTIVE OXYGEN SPECIES 
 
Reactive oxygen species (ROS) are the inevitable byproducts of aerobic metabolism, 
including a variety of molecules and free radicals derived from molecular oxygen
11
. It 
was reported that about 2% of electrons leak from the respiratory chain and form 
reactive oxygen species
11
. There are three major types of ROS: superoxide (O2˙
-
), 
hydrogen peroxide (H2O2) and hydroxyl radical (HO˙). Superoxide is the precursor of 
other ROS, and is formed when oxygen gets one electron leaking from respiratory 
chain. Superoxide cannot pass through the lipid bilayer membrane of mitochondria. 
However, superoxide can be easily converted into hydrogen peroxide by the catalyzing 
of superoxide dismutase (SOD)
12
. Hydrogen peroxide is not a radical molecule, but it 
can pass through membranes and diffuse freely in the cell. Hydrogen peroxide can be 
easily converted into highly reactive hydroxyl radical through a Fenton reaction 
(Reaction 1); at the same time the metal (Cu
+
 or Fe
2+
) is oxidized. The oxidized metal 
can also react with superoxide and convert it into an oxygen molecule (Reaction 2). 
The net reaction is called Haber-Weiss reaction (Reaction3). Hydroxyl radical is high 
reactive and can react with DNA, lipids, amino acids and carbohydrates
13
.  
 
Fe
2+
 (Cu
+
) +H2O2   Fe
3+
 (Cu
2+
) +OH
-
 + HO˙                                                  (1) 
 
Fe
3+
 (Cu
2+
) + O2˙
-
   Fe2+ (Cu+) +O2                                                                 (2)   
 
O2˙
-
+H2O2   HO˙+OH
-
 +O2                                                                              (3)    
 
Besides the respiratory chain, the other sources of ROS are NADPH oxidase (Nox), 
glucose oxidase, lipoxygenases, nitric oxide synthase, xanthine oxidase and 
flavoprotein reductases
14
. 
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1.3 THIOREDOXIN SYSTEM 
 
Thioredoxin system, composing thioredoxin (Trx), thioredoxin reductase (TrxR) and 
NADPH, plays an important role in maintaining cellular redox homeostasis and 
protecting cells from oxidative stress
15
. Trx executes its function by reducing the 
disulfide in its target proteins (Reaction 4), or binding to its substrate as a regulator. 
Oxidized Trx can then be reduced by TrxR, and NADPH is the ultimate electron donor 
for the system
16
 (Reaction 5). There are two distinct thioredoxin systems in mammalian 
cells: Trx1 system mainly in cytosol and nucleus, and Trx2 system in mitochondrial 
matrix
17
.  
 
Trx-(SH)2 + Protein-S2   Trx-S2 +Protein-(SH) 2                                          (4)    
 
Trx-S2+NADPH+H
+ TrxR  Trx-(SH) 2 + NADP
+ 
                                             (5)    
 
1.3.1 Thioredoxin 
 
Thioredoxin was first isolated and characterized by Peter Reichard and co-workers 
from E. coli as the electron donor for ribonucleotide reductase (RNR)
18
. Trx1 is a 12 
kDa globular protein ubiquitously expressed in various species. Besides being an 
electron donor for RNR, which is the rate limiting enzyme in the DNA synthesis by 
reducing ribonucleotide diphosphates (NDPs) to deoxyribonucleotide 
diphosphates(dNDPs)
19
, Trx1 can also reduce methionine sulfoxide reductase and 
peroxiredoxins in cytosol, thus plays important roles in cellular defense against 
oxidative stress and regulating H2O2 signaling
20,21
. Trx1 were also found to interact 
with several transcription factors such as NF-κB, Ref-1, and p5317,22–24. The regulation 
of its substrates and the transcription factors will be discussed in detail later. 
 
Mitochondrial Trx2 was first cloned and expressed as a 18 kDa mitochondrial protein 
with an N-terminal extension of 60 amino acids as a translocation signal
25
. Prx3 is the 
primary substrate of Trx2 in mitochondrial matrix, which is at the forefront of 
defending oxidative stress by eliminating excess hydrogen peroxide (H2O2). In 
addition, Trx2 can bind to ASK1 and regulate its function in mitochondria-dependent 
apoptosis
26,27
. Trx2 is also important in keeping mitochondrial permeability 
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transition
2,28
. Both Trx1 and Trx2 possess critical role in cell survival, and the mice 
with homozygous knockout of Trx1 or Trx2 both showed early embryonic lethality
29,30
. 
 
Both Trx1 and Trx2 belong to thioredoxin fold protein family
31
. In both structure, there 
is a central core of five β-strands which are surrounded by four α-helices (Fig. 1)32. The 
highly conserved active site (-Trp-Cys-Gly-Pro-Cys-) at the N-terminal of helix 2 
(Cys32 and Cys35 in orange in Fig. 1).  Besides the active site cysteine residues, there 
are three additional cysteine residues in Trx1, Cys62, Cys69 and Cys73. Cys73 
protrudes from the surface, and it is known that under oxidative stress Trx1 can form 
homodimer through a disulfide formed by Cys73 of two Trx1 molecules
33,34
. After 
dimerization, Trx1 will lose its activity due to the active site is not accessible to TrxR 
anymore
34
. Dimerization of Trx1 can also be found in cells under oxidative stress, but 
the physiological function of the dimer is not clear
35
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cys62 and Cys69 can form a second disulfide in Trx1, and accumulating evidence 
showed that the second disulfide may also play an important role in regulating Trx1´s 
function. Trx1 with two disulfide loses its function as a disulfide reductase and cannot 
be reduced by TrxR any more
36,37
. A recent finding in our group showed that Trx1 with 
two disulfides can be found in A549 cells under very oxidizing environment, and it is a 
 
Cys73 
Cys69 
Cys62 
 Cys32 
Cys35 
Figure. 1 Crystal structure of human Trx1
32
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substrate of Grx system, both in vitro and in cells
38
. In our ongoing study (Paper IV), 
we found that the Trx1 with two disulfides or with only the disulfide between Cys62 
and Cys69 is weakened the efficiency of reducing oxidized Prx1. All these findings 
suggested the biological function of the second disulfide in Trx1, although the exact 
mechanism is still unclear.  
 
1.3.1.1 Thioredoxin Substrates 
 
1.3.1.1.1 Ribonucleotide Reductase (RNR) 
 
RNR is the rate-limiting enzyme in DNA synthesis and repair by reduction of 
ribonucleotides (NTPs) to deoxyribonucleotides (dNTPs)
19
. Mammalian RNR is 
composed of two subunits: R1 and R2. R1 expresses constantly in the cells, while R2 
only present during the S phase, which make it to be the rate limiting factor for enzyme 
activity. Each cycle of reduction of NTPs to dNTPs results in a disulfide between the 
active site Cys residues in R1 subunit. However, the narrow structure of the active site 
in R1 does not allow the access of Trx1 to reduce it directly
39
. But  two Cys residues 
located in the mobile tail of the C-terminal of R1 can be reduced by Trx1 and then 
transfer the reducing equivalent to the active site disulfide
40
. Evidence from 
mutagenesis of E. coli R1 subunit suggest the critical role of C-terminal cysteines in 
reducing R1 active site
41,42
. Our result using the peptide containing 25 amino acid 
residues from C-terminal of R1 subunits also proved that it is the substrate of Trx1 
(unpublished data).  
 
Additionally, both Trx and Grx can provide electrons for RNR in mammalian cells, but 
through different mechanisms. By using recombinant mouse RNR, Trx1 and Grx2 
showed very similar catalytic efficiency, but the Grx activity largely depended on GSH 
concentration, which suggest a GSH-mixed disulfide mechanism for Grx instead of the 
disulfide exchange mechanism for Trx
43
. 
 
1.3.1.1.2 Peroxiredoxin 
 
Peroxiredoxin (Prx) was first identified as a substrate of Trx by Dr. Sue-Goo Rhee and 
his group in 1994
44
. Besides its ability of removing access H2O2 to protect cells from 
oxidative stress, Prx is also proposed to serve the function to control the redox signaling 
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through sensing and regulating H2O2
45–47
, which was justified as a messenger molecule 
more than just evil oxidant. There are six Prxs in mammalian cells (Prx1 to Prx6), and 
they are classified into three groups: Prx1 to Prx4, which all possess an active site 
comprising conserved N-terminal cysteine and C-terminal cysteine, are classified into 
the 2-Cys subfamily; Prx5, also known as atypical 2-Cys Prx, which have very similar 
N-terminal cysteine sequence compare to the 2-Cys Prxs, but lack the C-terminal 
conserved sequence containing cysteine residue
48
. The Cys151 serves the role as the C-
terminal cysteine in Prx5. Prx6, which only have one cysteine residue, is termed as 1-
Cys Prx
49
.  
 
The typical 2-Cys Prxs are present as homodimers in mammalian cells. The Cys-SH in 
the N-terminal of one subunit is very sensitive to H2O2 and can be easily oxidized into 
Cys-SOH, which then reacts with the C-terminal Cys-SH of another subunit to generate 
an intermolecular disulfide. Then the disulfide can be reduced by Trxs. All four 
members of 2-Cys Prxs are substrates of Trxs
50
. In Prx5, which also exists in a dimer 
form, the N-terminal Cys residue is oxidized into Cys-SOH, which then react with the 
Cys151 in the same subunit and forms an intramolecular disulfide
48,51
. Prx5 can also be 
specifically reduced by Trx. Prx6, however, is not a substrate of Trx, because it cannot 
form disulfide upon oxidation
52
.  
 
1.3.1.1.3 Methionine Sulfoxide reductase 
 
Both free methionine (Met) and methionine in proteins are easy to be oxidized into 
methionine sulfoxide (MetSO) under mild oxidative condition. According to different 
asymmetric forms, the oxidation of Met can result in either Met-(S)-SO or Met-(R)-SO. 
The oxidation of Met into MetSO affects the protein functions
53
. The methionine 
sulfoxide reductase (Msr) can reduce both the free and protein-bound MetSO residues. 
According to their different substrate specificities, there are two types of Msrs: MsrA 
which can reduce the Met-(S)-SO; and MsrB which reduces Met-(R)-SO
54,55
.  
 
The catalytic mechanism of Msrs is quite similar to atypical 2-Cys Prx. First, the 
“catalytic” Cys residues interact with the sulfoxide group of Met and form a sulfenic 
acid intermediate. Then the second Cys residue referred as “recycling” Cys residue 
comes into play and results in the formation of an intramolecular disulfide between the 
two Cys residues, which can then be reduced by Trx
54
. 
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1.3.1.2 Transcription Factors regulated by Trx 
 
The regulation of many transcription factors by Trx mainly depends on the activity of 
Trx to reduce the cysteine residues in the DNA binding domain of these transcription 
factors, directly or indirectly. 
 
1.3.1.2.1 Nuclear Factor –κB (NF-κB) 
 
Various oxidative stresses, such as UV and H2O2, and some toxic compounds such as 
cigarette smoke and lysophosphatidic acid can induce the activation of NF-κB56,57, 
which controls several inflammation genes. Under normal condition, NF-κB binds with 
IκB as an inactive complex in cytosol. Under oxidative stress or other type of stimuli, 
the IκB is phosphorylated by IκB kinase. Upon the phosphorylation, IκB is degraded 
and NF-κB is released to be free. The free NF-κB can then translocate from cytosol to 
nucleus to exert its function as a transcription factor
58–60
.  
 
In nucleus, binding of DNA requires the reduced Cys62 in its p50 subunit. The 
reduction of Cys62 requires reduced Trx, on the other hand, oxidized Trx inhibits the 
binding of NF-κB to DNA23,61. In the cytoplasm, however, Trx plays distinct roles in 
regulation of NF-κB activation by preventing the dissociation and degradation of IκB 
from NF-κB62. 
 
1.3.1.2.2 Redox Factor -1 (Ref-1) and Activator Protein – 1(AP-1) 
 
AP-1 controls the transcript of many gene involving in cell growth. The DNA binding 
activity of AP-1 is dependent on Trx’s activity; however, Trx1 does not directly interact 
with the Cys residues in Ref-1, but exert its reducing power through a redox factor 
called Ref-1. In vitro experiments showed that Trx1 can form a heterodimer with Ref-1 
through its active site Cys-32. Upon the dissociation of Ref-1 and Trx1, Ref-1 can 
reduce Cys residues in the DNA binding domain of AP-1 (Fos and Jun subunits)
63,64
.  
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1.3.1.2.3 Tumor Suppressor p53 
 
After activated by series of stress signals, such as oxidative stress, hypoxia, DNA 
damage agents, etc., p53 controls the transcription of proteins related to cell cycle 
arrest, DNA repair, and apoptosis. The mutation of p53 will result in the loss of control 
of above mentioned cellular process, and leads to tumor genesis. P53 mutations are 
observed frequently in various types of human cancers
65,66
.  The sequence-specific 
DNA binding ability relies on the reduction of the Cys residues in the DNA binding 
domain of p53
67
. Although there is no evidence showing the direct binding of p53 with 
Trx, many studies showed that Trx can enhance the DNA biding activity of p53 by 
itself, or through the activation of Ref-1
22,68,69
. In addition, deletion of TrxR in yeast 
strongly impaired p53 activity
70
. In mammalian cells, several electrophilic compounds 
which can damage TrxR activity also showed disruption of the function of p53
71
. 
 
1.3.1.3 Proteins binding to Trx 
 
Besides above mentioned enzymatic activities, there are several proteins are known to 
bind to Trx. Two of the well-studied ones are Apoptosis Signal-regulating Kinase 1 
(ASK1) and thioredoxin interacting protein (Txnip). 
 
1.3.1.3.1 Apoptosis Signaling Kinase -1 (ASK1) 
 
ASK1 is a mitogen-activated protein kinase kinase kinase (MAPKKK). ASK1 first can 
activate MAP kinase kinase, which then activates two apoptosis pathways: c-Jun N-
terminal kinase (JNK) and p38 MAP kinases pathways
72
. Trx inhibits the activation of 
ASK1 by directly binding to it and disturbing its homo-oligomerization
73
. The binding 
of Trx and ASK1 requires the involvement of at least one active site Cys residue 
(Cys32 or Cys35). A double mutant Trx1(Cys32S, Cys35S) cannot bind to ASK1
74
. 
The binding of Trx also promotes the ubiquitination and degradation of ASK1
74
. 
Besides Trx1, several studies have shown that Trx2 in mitochondria can also interact 
with ASK1, and inhibits its translocation and activation
26,75,76
.  
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1.3.1.3.2 Thioredoxin interacting protein (Txnip) 
 
Txnip, which was first found in HL-60 leukemia cells as a vitamin D3 up-regulated 
protein-1 (VDUP1)in 1995
77
. In 1999, Txnip was rediscovered as thioredoxin binding 
protein in a yeast two-hybrid system and termed as thioredoxin binding protein-2 
(TBP2)
78
. The binding of Txnip with Trx is through formation of an intermolecular 
disulfide bond between Cys32 from Trx and Cys247 from Txnip
79,80
. The formation of 
this disulfide is redox-dependent, in order to archiving the binding, a reduced Trx and 
an oxidized Txnip are needed
79
. The binding of Txnip cause reduced Trx activity as a 
disulfide reductase, which results in elevated level of ROS in cells
81,82
. Txnip can also 
alter Trx's function as a competitive inhibitor and disturbs the interaction between Trx 
and its targeting proteins, such ASK1
27,82
. Recently, the structure of the complex of Trx 
and Txnip has been determined. The structure confirmed the disulfide formation 
between Txnip Cys247 and Trx Cys32, in addition, a disulfide bond switching 
mechanism was proposed to explain the structural rearrangement in Txnip
80
.  
 
1.3.1.4 Regulation of Trx activity/function in cells 
 
The regulation of Trx activity/function can happen in different levels, including: 
expression, post-translational modifications and protein-protein interaction. Txnip is a 
well-known thioredoxin binding protein has its implications in regulating Trx activity 
and interaction with other proteins (see above).  
 
1.3.1.4.1 Expression 
 
Various stress, such as H2O2, O2, hypoxia, UV, X-ray, etc.
83–86
 and treatments of certain 
drugs such as arsenic trioxide and suberoylanilide hydroxamic acid (SAHA) 
35,87
can 
increase the expression of Trx1 in mammalian cells. After analyzing the promoter 
region of human TXN1 gene, there are three types of stress-response elements were 
found in the promoter region, including: antioxidant responsive elements (ARE), 
oxidative response element and heat shock responsive element
88–90
. These findings can 
explain the induction of Trx1 expression under multiple stresses.  
 
Under some conditions, such as hypertension, and the treatment of certain compounds 
such as cathepsin D, the amount of Trx is reported to be decreased may be due to the 
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impaired induction of Trx1 and the degradation of damaged protein during oxidative 
stress
91,92
. It is interesting to point out, for the treatment with the same drug, SAHA, 
which is the histone deacetylase inhibitor, contradictory results were given by different 
studies. In some study, expression of Trx1 was found to be positively regulated
87
, while 
in another study, expression of Trx1 was shown to be negatively regulated
93
. These 
difference may due to the differences between cell types, the amount of the treatment, 
and maybe some other factors.  
 
1.3.1.4.2 Post-translational modifications 
 
Oxidative post-translational modifications of the Cys residues in Trx1 were 
investigated extensively, three types of modifications are the center of interest: 
oxidative modification of the Cys residues (through disulfide formation), S-
glutathionylation and S-nitrosylation. The modification of each Cys residue is briefly 
summarized in Table 1.  
 
There are five Cys residues in human Trx1, two of them are involved in the active site 
(Cys32 and Cys35) which are required for the activity of Trx and the interaction of 
Trx1 with its interacting proteins
74,79
. The rest three Cys residues, as known as 
structural cysteines, first caught the attention because they cause the aggregation and 
loss of activity in Trx1
94
. Although until now their physiological functions are still not 
clear, but accumulating evidence suggesting these cysteine residues may also involve in 
the redox signaling. Homodimerization of Trx1 is through the disulfide formed 
between two Cys73 residues from each molecule
33
. Trx1 dimer does not have any 
reduce activity because the active site was not accessible for TrxR
37,95
. Under oxidative 
environment, an extra disulfide can form between Cys62 and Cys69. Trx1 with only the 
disulfide between Cys62 and Cys69 can be reduced by TrxR because the disulfide can 
be transferred to the active site. Trx1 with two disulfide is inactive and cannot be 
reduced by TrxR
16,96
, but is a substrate of Grx system
97
. Nevertheless, the formation of 
the second disulfide in Trx1 may provide a redox mechanism regulating its function 
and earns more time for the redox signaling transduction
38,96
. 
 
S-glutathionylation is a reversible oxidative post-modification. Both in vitro and in cells 
study showed that Cys73 can be glutahionylated under oxidative stress. The 
glutathionylated protein is inactivated, but the activity can be regained automatically 
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when incubated with TrxR and NADPH, suggesting the glutathionylation process is 
reversible
98
. Although glutathionylation can happen during physiological conditions, 
Trx1 can only be glutathionylated in oxidative stress environment. Thus, the 
glutathionylation may play an protection role against irreversible oxidative 
modifications, such as dimer formation which leads to loss of activity
99
. 
 
 
Table1. Post-translational modifications of Cys residues in Trx1 
 
Haendeler et al found that Trx1 can also be S-nitrosylation in 2002. They claimed that 
under physiological condition, Cys69 can be nitrosylated, and the nitrosylation of 
Cys69 stimulates Trx1’s function in redox regulation and anti-apoptosis100. However, 
several following studies gave controversial results. In one study, the S-nitrosylation of 
Cys69 was detected and no S-nitrosylation of Cys73 was detected, in addition a 
disulfide between the active site Cys residues was observed
101
. In a structure study, 
Cys 
residue 
  Post-Translational modifications   Change of  Trx1's activity / function 
           
Cys32  disulfide formation    Loss of activity but can be reduced 
by TrxR  Cys35  disulfide formation    
      
Cys62  extra-disulfide formation   
Loss of activity and cannot be 
reduced by TrxR 
  S-nitrosylation        
      
Cys69  extra-disulfide formation   
Loss of activity and cannot be 
reduced by TrxR 
  S-nitrosylation    
Stimulating Trx’s activity and anti-
apoptotic function 
         
Cys73  homodimerization    loss of activity   
  S-glutathionylation    loss of activity, but reversible 
  S-nitrosylation    
Trx can act as a trans-nitrosylation 
agent 
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after treated with GSNO, both Cys69 and Cys62 were found to be nitrosylated. There is 
no nitrosylation on Cys73, and a disulfide bond was formed in the active site
102
. A 
study from our group suggested that the different results obtained from these studies 
maybe because the redox state of Trx1 was difference when the experiments were 
performed. Treatment of GSNO resulted in nitrosylation of Cys69 and cys73 and an 
additional disulfide in the active site in fully reduced Trx1. Treating Trx1 with two 
disulfides under the same condition resulted in the nitrosylation of Cys73, which can 
act as a trans-nitrosylation agents, and cause the nitrosylation of caspase-3 and 
subsequently inhibit apoptosis
101,103
.    
 
1.3.2 Thioredoxin Reductase  
 
1.3.2.1 Classification 
 
Thioredoxin reductase (TrxR) belongs to the family of dimeric flavoenzymes that 
catalyze the electron transfer from pyridine nucleotides to their substrates through 
flavin adenine dinucleotide (FAD) and the active site with redox active cysteine 
residues 
104
. It is important to mention that there are two types of TrxRs which are 
classified according to the difference in the molecular weight of the subunit. The small 
TrxR or the low Mr type TrxR, comprising of two identical 35 kD subunits, which 
mainly exist in lower organisms such as bacteria, fungi, yeast and plants. The large 
TrxR or the high Mr type TrxR, comprising of two identical 55-60 kD subunits, which 
can be found in higher organism such as mammalians
104,105
. Besides the difference in 
the molecular weight, their catalytic mechanisms are also different. 
 
E. coli TrxR is a well-studied small TrxR. Here we use it as an example to discuss the 
catalytic mechanism of small TrxR. In each cycle of the reaction, there is an unique 
rotation of the pyridine nucleotide-binding domain by 67 degree
106
. The structure 
before rotation facilitate the reduction of FAD by NADPH
107
, while the structure after 
the rotation allows the transfer of electrons from reduced FAD to the active site 
disulfide
108
.  
 
Different from the small TrxR, the large TrxR comprises three functional domains in 
each subunit: FAD domain, NADPH domain and interface domain (Fig. 2). In each 
   13 
subunit, there are also two redox active sites: one located at the C-terminal active 
mobile tail, the other one is close to the FAD.  
 
The redox active site of the C-terminal tail is different from species to species. In some 
species, such as plasmodium falciparum (the malaria parasite) and Drosophila 
Melanogaster (fruit fly), the C-terminal redox active site is composed of two Cys 
residues; from C.elegans, the selenocysteine (Sec) replaces the last cysteine in the C-
terminal tail. Compared to Cys, Sec has a lower pKa value which makes it more active. 
The C-terminal tail is highly flexible and exposed on the surface of the enzyme upon 
reduction
109
.  
 
1.3.2.2 Catalytic properties of mammalian TrxR 
 
As shown in Fig. 2, the two TrxR monomers were arranged into a head-to-tail dimer. 
The two redox active sites are close to each other in space, although one of them is 
located in the FAD binding domain (Cys59 and Cys64), while the other is located in 
the C-terminal of the interface domain (Cys497 and Sec498). In each catalytic cycle, 
the fully oxidized TrxR is first reduced by NADPH and the FAD gains two electrons 
upon the reduction; then the reduced FAD transfers one electron to Cys59 and shares 
the other one with Cys64; after the stable charge transfer complex is formed in N-
terminal active site, it can reduce the C-terminal of the other subunits; this reaction 
results in the reduced C-terminal selenothiol and a disulfide in the N-terminal active 
site; FAD can again reduce the N-terminal disulfide through transferring electrons from 
NADPH
109,110
.  
N-terminal CVNVGC 
active site 
FAD domain 
NADPH domain 
Interface domain 
C-terminal GCUG tail 
Figure 2. Schematic overview of TrxR structure. 
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1.3.2.3 Isoforms of TrxR 
 
In mammalian cells, there are three separate genes encoding three isoforms of TrxR: 
TrxR1, which is mainly present in cytosol; TrxR2, which is only present in the matrix 
of mitochondria; and thioredoxin glutathione reductase (TGR), which has a Grx 
domain in the N-terminal sequence, and mainly expresses in testes. TrxR1 and TrxR2 
have similar kinetic properties
111
, whereas TGR can reduce both Trx and GSSG, and 
also has a low Grx activity. But the Grx activity of TGR is not GSH-dependent since 
the C-terminal Sec residue may be able to transfer electrons to the Grx domain
112,113
. 
TGR can catalyze the formation of intermolecular disulfide bonds and protein 
isomerization, indicating its role in protein folding. In testes, TGR and its target protein 
GPx4 can serve as a disulfide bond formation system, including proteins that form the 
structural components of the sperm, suggesting its role in sperm maturation
114
. 
 
Besides these three isoforms of TrxR, there are many splicing variants of TrxR1 and 
TrxR2. For example, five different cDNA isoform of TrxR1 have been discovered 
which all have alternative N-terminal domains
115,116
. The biological functions of these 
variants are still under investigation.  
 
1.3.2.4 Selenoproteins 
 
Selenium is an essential trace element for human, and deficiency of selenium in dietary 
uptake can result in loss of immune function, weakened reproduction, depression and 
cardiovascular diseases
117
. One important application of selenium by mammals is the 
synthesis of selenoproteins. Until today, there are about 25 selenoproteins that have 
been identified in human by searching the mammalian genomes
118
. Most of these 
selenoproteins are found to be antioxidant enzymes, such as TrxR1 and TrxR2, 
methionine-R-sulfoxide reductase B1, GPx1 to 4 and 6, SelK, SelW and SelR. Other 
important selenoproteins are selenoprotein P (SelP) which functions in the Sec residue 
transport and storage due to the highly toxicity of free Sec residue; selenophosphate 
synthetase 2 (SPS2) functions in Sec synthesis, etc. The functions of some 
selenoproteins are still unknown. 
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The Sec is encoded by a UGA codon, which is in most cases recognized as a stop 
codon. In order to correctly recognize the codon and insert the Sec into the right 
position, a complex regulatory mechanism has been developed in mammalian cells. 
First of all, a secondary RNA structure called the SECIS element is used in the 3'UTR 
of the RNA message. In addition, a special translation machinery is required as well, 
including: a Sec specific tRNA, the specific elongation factor EFSec, SECIS binding 
protein 2 (SBP2), ribosomal L30 protein, and many other factors including some may 
be undiscovered factors
119
.  
 
1.3.2.5 Selenocysteine v.s. cysteine 
 
Compared to Cys residues, the only difference of a Sec residue is the replacement of -
SH by -SeH (Fig. 3). However, the insertion of one Sec is very expensive for cells, 
which suggests the irreplaceable advantages of Sec over Cys residue. Upon the 
replacement of sulfur by selenium, the pKa value of the residue is changed from 8.3 in 
Cys to 5.2 in Sec. This change in the pKa value result in an almost completely 
deprotonated selenolate at the physiological pH, which is more reactive comparing to 
thiol
120
. Actually under selenium deficiency condition, the Sec residue in TrxR was 
found to be replaced by a Cys residue in rat liver, resulted in a 10 fold decrease in TrxR 
activity
121
.  
 
  
Figure 3. Chemical structure of Selenocysteine and cysteine. 
 
1.3.3 Thioredoxin system in cancer 
 
The ROS level in cancer cells was shown to be elevated compared to normal cells, 
which may be due to defects in the respiratory chain and disturbed redox balance
122
. A 
moderate elevated ROS is preferred by cancer cells because it can promote tumor 
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growth and survival by stimulating the expression of enzymes, such as mitogen-
activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) and 
cyclin D
123
. Trx and TrxR were also found to be overexpressed in many cancer cells, 
and they play important roles in cancer cell death
24,124
. Targeting Trx and/or TrxR can 
induce a massive increase in ROS level, and  induces cell death through multiple 
pathways, such as activation of ASK1, translocation of cytochrome c from 
mitochondria to cytosol and induction of p53 expression, etc
27,29,125
.These studies 
suggest the cellular redox pathways, such as Trx system, can be a promising target in 
anticancer therapy. 
 
Table 2. Compounds used in the thesis    
       
Chemical    Effects on TrxR/Trx  Paper 
             
Auranofin   Inhibitor of TrxR Ⅲ 
       
Arsenic trioxide  Inhibitor of TrxR Ⅳ 
       
Arsenic compound 6  Inhibitor of TrxR  Ⅳ 
   specific oxidation of Cys62 and Cys63 in Trx1 
       
Arsenic Compound 7  Inhibitor of TrxR Ⅳ 
   Two disulfide formation in Trx1  
       
Brilliant Green  Inhibitor of TrxR(in vitro unpublished data) Ⅰ 
   Cause Trx2 degradation  
       
Ebselen   Super-fast oxidizer of  Trx  Ⅱ 
   Substrate of both Trx and TrxR  
       
4-hydroxynonenal  Inhibitor of TrxR  Ⅲ 
       
Mercury   Inhibitor of TrxR  Ⅵ 
       
Mitomycin C   Inhibitor of TrxR   Ⅴ 
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TrxR emerges as a new anti-cancer therapeutic target, and has a long list of inhibitors. 
The selenocysteine in the C-terminal active site is found to be a primary target of 
several electrophilic compounds, such as are anticancer drugs such as cisplatin, 
mitomycin C, doxorubicin, etc.
126–128
 Several anticancer compounds, or clinically 
applied drugs have also shown the ability of interfere the expression level of 
thioredoxin or change its redox state
87,91,129
. Table 2 exhibits the compounds studied in 
this thesis.  
 
1.4 GLUTAREDOXIN SYSTEM 
 
Besides Trx system, glutaredoxin system composed of glutaredoxin (Grx), glutathione 
reductase (GR), glutathione (GSH) and NADPH is another major cellular protein 
disulfide reductase system. GSH is the most abundant small thiol-containing molecules 
in cells, which concentration can reach up to 10-15 millimolar levels. The reaction of 
protein-disulfide reduction catalyzed by Grx system has two distinct mechanisms. One 
is the thiol/disulfide exchange mechanism, which is similar to Trx system, called dithiol 
mechanism. The other one is the so called mono-thiol mechanism, in which only the N-
terminal active site Cys residue is involved.  
 
In a dithiol mechanism, Grx with two free thiols in the active site first reduces the 
disulfide in the substrate through a thiol-disulfide exchange mechanism, and results in a 
disulfide formation in the active site (Reaction 6). The disulfide in Grx's active site can 
then be reduced by gaining electrons from two molecule of GSH, results in the 
formation of one GSSG (Reaction 7). Finally, GSSH is reduced to two GSH by GR 
using electrons from NADPH (Reaction 8).  
 
Grx-(SH)2
 
+ Protein-S2   Grx-S2 + Protein-(SH)2                                          (6)  
 
Grx-S2 + 2 GSH        Grx-(SH)2 + GSSG                                                      (7)  
 
GSSG + NADPH + H
+ GR  2GSH + NADP+                                                    (8)  
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The monothiol mechanism is actually a deglutathionylation reaction
130
. First, GSH can 
form a mix-disulfide with protein thiol, and then reduced Grx can form a new mixed-
disulfide between its N-terminal active site Cys residue and the GSH, and transfer the 
electron the protein thiol, which is reduced (Reaction 9). The resulting mixed-disulfide 
is subsequently reduced by another molecule of GSH, results in the fully reduced Grx 
and a GSSG (Reaction 10); this is the rate limiting step of the whole reaction
131
 . 
Finally, GSSG is reduced in the same way as reaction (8).  
 
Grx-(SH)2 + Protein-S-SG   (N-terminal)GS-S-Grx-SH (c-terminal) + Protein-SH     (9)    
 
GS-S-Grx-SH +GSH       Grx-(SH)2 +GSSG                                                   (10)          
 
1.4.1 Glutaredoxin 
 
Grx was first discovered in 1976 by Arne Holmgren as a GSH dependent electron 
donor for RNR in E. coli lacking Trx system
132
. Grx is a Trx fold family protein with 
conserved active site sequence -Cys-X-X-Cys-
133
. There are three different isoforms of 
Grxs in mammalian cell: Grx1 is located in cytosol, Grx2 is located in mitochondrial, 
and Grx5, which is a monothiol isoform and may be also target mitochondria
134
. 
 
Cytosolic Grx1 is about the same size of Trx1 (~12 kDa), which structure comprises a 
Trx fold with a central core of four β-sheets surrounding with five α-helixes. The 
conserved active site (-Cys-Pro-Tyr-Cys-) locates in the N-terminal part of helix 2 in 
mammalian Grx1
135
. The structure of reduced and oxidized Grx2 are very similar, only 
slightly changes around the N-terminal active site area
136
. The structure of E. coli Grx1 
revealed a GSH binding site and a mixed-disulfide with GSH which can explain the 
high specificity and affinity of Grx to GSH
137
. In addition, Grx also has a hydrophobic 
surface area around the active site, which facilitates the interaction of Grx with its 
substrate
136
. The same as Trx1, Grx1 can also translocate into nucleus upon oxidative 
stress, where it may exert its role in regulating transcription factors.  
 
Human Grx2 has two isoforms, Grx2a and Grx2c. Grx2a is located in mitochondria, 
while Grx2c is localized in nucleus, and cytosol of some tumor cells
138
. Under reducing 
condition, two molecule of Grx2 and two GSH form heterodimer through iron-sulfur 
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cluster
139
. The dimeric Grx2 is enzymatically inactive. But upon oxidative stress, Grx2 
is dissociated and activated. This property of Grx2 suggests its role as a redox sensor, 
and the importance of it as a backup reductase under oxidative stress
140
. Compared to 
Grx1, Grx2 has a higher affinity to the S-glutathionylated protein substrates with lower 
turnover rates
141
. Grx2 can catalyze the reversible oxidation and glutathionylation of 
mitochondrial membrane thiol proteins, and plays important role in mitochondrial 
redox signalling and oxidative stress defense.
142
. 
 
Grx5 is named because it is a homologue of yeast Grx5. Grx5 is also located in 
mitochondrial but with only one Cys residue in its active site, and so far no redox 
activity has been reported
134
. Its role in mammalian cells is not clear yet , but in yeast 
Grx5 is found to be involved in the synthesis of iron-sulfur clusters and regulation of 
the activity of iron-sulfur enzymes
143
. 
 
1.4.2 Glutathione Reductase 
 
GR is a flavoenzyme responsible for maintaining the reduced GSH pool in cells. The 
same as TrxR, GR is also belonged to the pyridine nucleotide disulfide oxidoreductase 
family. The active form of enzyme is a dimer with two identical subunit arranged into a 
"head to tail" pattern. Each subunit of GR also contains three domains: FAD binding 
domain, NADPH domain and interface domain
144
. The redox active site in the N-
terminal (-Cys-Val-Asn-Val-Gly-Cys-) is homology to TrxR and is conserved in many 
species. When reducing GSSG, two electrons from NADPH was first transferred to 
FAD, and then transferred to the active site. Finally, GR reduces GSSG in a 
thiol/disulfide exchange manner. There is only one gene in mammalian cells encoding 
GR, although there are GR presenting both in cytosol and in mitochondrial. GR from 
different subcellular compartments has the same biological and chemistry properties
145
 
 
1.4.3 Glutathione 
 
GSH is a tripeptide (L-γ-glutamyl-L-cysteinylglycine), and is the most abundant thiol-
based antioxidant in mammalian cells. The ratio between reduced GSH and oxidized 
GSSG (GSH/GSSG) is used as the indicator of cellular redox state. In a physiological 
state, the ratio can be above ten in the cytoplasm. The synthesis of GSH is a two steps 
ATP dependent reactions happens in cytosol: first is the rate limiting step of the 
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synthesis, γ-glutamyl-cysteine is synthesized from L-glutamate and cysteine through 
the catalysis of γ-glutamyl-cysteine synthetase (also called glutamate cysteine ligase, 
GCL)
146
. Then a glycine was added into the dipeptide by the catalysis of glutathione 
synthetase. The synthesis of GSH is regulated by many factors, such as oxidative stress 
which can enhance the activity of GCL by increase the holoenzyme formation; the 
availability of L-cysteine; and regulation of GCL and glutathione synthetase at 
transcriptional level
147
. 
 
After GSH is produced in cytosol, it can be transported into different subcellular 
compartments, providing different redox environment in different organelles in a cell. 
For example, GSH can be transported into mitochondria through both a carrier 
mediated pathway and diffusion
148,149
. Mitochondria contain a higher amount of GSH 
compare to cytosol or nucleus, and the pool of GSH in mitochondria has a longer half-
time. When using buthionine sulfoximine (BSO), which is an inhibitor of GCL, to 
deplete cellular GSH, the GSH in mitochondria is much more resistant compared to 
cytosol
150,151
. These results suggest that GSH in mitochondria protects cells from 
oxidative stress when the pool in cytosol is low or oxidized. Another example is that in 
endoplasmic reticulum (ER), where the environment is much more oxidized than other 
parts of the cell, the ratio of GSH/GSSG is about 3:1. The oxidizing environment in ER 
can facilitate protein folding
152
. Besides the transportation within cell, GSH can also be 
transported outside cells, but mostly in oxidized form (GSSG). The extracellular GSH 
is much lower than intracellular, for example in plasma there is only about 2-20µM 
GSH, and the ratio between reduced GSH and oxidized GSSG in plasma decreases by 
aging, especially after 45 years of age
153,154
.  
 
Besides its role in protecting cells from oxidative stress, GSH participates in many 
cellular processes through S-glutathionylation, an important post-translational 
modification of proteins. Via S-glutathionylation, the target protein can either be 
activated or inactivated
155
. A large group of proteins can be regulated through 
glutathionylation, and involve in many important physiological pathways such as cell 
metabolism, growth and differentiation. Some transcription factors, such as AP-1 and 
NF-κB can also be glutathionylated and loss their ability of binding to DNA156–158. As 
mentioned before, Cys73 in Trx1 can also be glutathionylated, this modification may 
be able to protect protein being irreversibly oxidized, in the case of Trx1, forming 
inactivated dimer through Cys73
98,159
.  
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In addition, GSH is implicated in the metabolism and detoxification of several toxic 
compounds. For example, after entering cells, pentavalent arsenic needs to be reduced 
in to trivalent arsenic in a GSH-dependent pathway, and then conjugated with GSH in 
order to be exported out of cells
160
.  
 
1.4.4 Cross-talk between Trx and Grx System 
 
In mammalian cells, glutaredoxin system has some functions overlapping with 
thioredoxin systems. For example, both systems are electron donors for RNR with 
similar catalytic efficiency. With the present of 4 mM GSH, Grx1 showed a higher 
affinity compare to Trx1, but the later has a higher turnover number in vitro. 
Meanwhile, the catalytic activity of Grx system was strongly dependent on the 
concentration of GSH, and the catalytic reaction is more likely to follow the monothiol 
mechanism, which can be distinguished from the dithiol mechanism of Trx
43
. Other 
overlapping functions including their role in protecting cells from apoptosis, Grx1 can 
also negatively regulate ASK1’s activity, though the binding site is different from 
Trx1
161
. Grxs are also reported to be able to regulate some transcription factors, such as 
NF-κB and nuclear factor I (NFI)162,163.  
 
Although there is much overlap in their functions, they cannot fully substitute for each 
other due to their difference in the selection of substrate groups and different reaction 
mechanism. Generally, Trxs reduce the disulfide in its substrates through a 
thiol/disulfide exchange mechanism, which is similar to the dithiol mechanism of Grxs. 
Prxs are specific substrates of Trx system, which is in the forefront of defending 
oxidative stress by elimination excess H2O2
45
. Grx system can exert its anti-oxidant 
function by providing electrons to glutathione peroxidases (GPxs), a family of enzymes 
which are also involved in balancing H2O2 homeostasis and multiple cellular signaling 
pathways including carcinogenesis, apoptosis, etc.
164
. In addition, Grxs can catalyze the 
reversible deglutathionylation reaction of its substrates through the so called monothiol 
mechanism as described previously in “Glutaredoxin” section. 
 
Apart from the similarity and difference of their substrates and functions, Trx and Grx 
system can back up each other when the enzyme in one system does not function. Grx2 
can be reduced by both GR and TrxR
141
. Trx can reduce GSSG in GR-deficient cells
165
. 
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A study from our group showed that Grx system could work as a backup for TrxR and 
keep Trx1 in the reduced condition when TrxR1 was inhibited
166
. Moreover, the 
heavily oxidized Trx1 with two disulfides cannot be reduced by TrxR but can be 
reduced by Grx system at the expense of GSH
97
. Besides the finding in the cytosol, we 
also found that Grx2 is a very good back up for TrxR2 in mitochondria, and keep Trx2 
in the reducing state when TrxR2 was inhibited. In Hela cells, which also express 
Grx2c in the cytosol, Grx2c can also protect Trx1 from being oxidized when TrxR1 is 
inhibited
167
. Under reducing environment, Grx2 is inactive and stored in dimer form 
together with two GSH through iron-sulfur cluster
139
. Upon oxidative stress, Grx2 will 
be released and activated to exert its anti-oxidant function. This fact together with its 
property of less sensitive to oxidative stress damages
103
, make Grx2 very fit for being a 
backup for TrxRs. 
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2 AIM OF THE THESIS 
 
As indicated in the title, our primary goal was to explore the role of Trx and TrxR in 
cell death caused by toxic compounds, as well as to investigate the potential possibility 
of Trx and TrxR as targets for anticancer therapy. 
 
Specifically, in Paper I - IV we focused on studying the role Trxs in cell death and the 
properties of the protein. 
 
 To investigate the role of Trx2 in some cationic triphenylmethanes causing 
cancer cell death. 
 To characterize if Trx1 with two disulfides is a substrate of the Grx system and 
its possible role in redox signaling 
 To characterize Grx2 as a backup system for both Trx1 and Trx2. 
 To investigate if the oxidation of Trx1 can enhance the cytotoxicity of some 
arsenic compounds, and the role of Cys62 and Cys69 in regulating the function 
of Trx1 
 
In Paper V and Paper VI, we focused on the inhibition of TrxR by toxic compounds or 
clinically applied anticancer drug. 
 
 To investigate targeting TrxR as a new anticancer mechanism of mitomycin C. 
 To study targeting TrxR as a new mechanism of mercury toxicity, and the role 
of selenium in recovery of the activity of TrxR inhibited by mercury. 
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3 PRESENT INVESTIGATIONS 
 
3.1 METHODOLOGY 
 
3.1.1 Cell Culture 
 
For most cell based experiments described in papers I-VI, commercially available 
human cell lines from the American Type Culture Collection were used. Fibroblast 
cells in paper I was a gift from Dr. Laura Papp, Queensland Institute of Medical 
Research, Australian. Hela cell (human cervical carcinoma), A549 (human alveolar 
adenocarcinoma epithelial cell), SH-SH5Y (human neuroblastoma) and Du145 (human 
prostate cancer) were cultured in Dulbecco's modified Eagle's medium (DMEM) with 1 
g/l glucose (VWR). HEK293t (human embryonic kidney cell) and Fibroblasts were 
cultured in RPMI 1640 medium with 1 g/l glucose (VWR).  
 
3.1.2 RNA Silencing 
 
The transfection of siRNA in Paper I and Paper III was performed according to the 
Dharmacon transfection protocol. Briefly, siRNA transfection reagent (Dharmacon, 
Lafayette, Co, USA) and siRNAs (Qiagen, Valencia, CA, US) were diluted in serum 
and antibiotic-free medium and left at room temperature for 5min. Then the siRNA 
transfection reagent and siRNA were mixed and incubated for 20 min. Complete 
medium were added into the mixture to achieve a final concentration of 50 nM siRNA 
in the culture medium. After 48 hours incubation, the medium was removed, and the 
cells were harvest for analysis or continue incubated with the desired compounds.  
 
3.1.3 Cell Proliferation and Viability Assays 
 
The most commonly used assay for cell proliferation and viability measurement in all 
six papers is the MTT assay. Because MTT assay can be affected by the alteration of 
mitochondrial metabolism, in order to confirm the results of MTT assay, we also used 
trypan blue exclusion and neutral red up take assay to investigate the effects of 
compounds we used on cell viability in some of our studies. Observations of the 
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morphology of cells by microscopy were always performed and recorded prior to each 
assay.  
 
For MTT assay, cells were plated at a density of 1×10
4
 cells/well in 96-microwell plate 
and allowed to grow about 24 hours to get confluence. Then the cells were treated with 
appropriate concentrations of compounds in 100 µl fresh medium for the appropriate 
time. After treatment, medium containing compounds were replaced by 100 µl of fresh 
medium, and 50 µl of MTT solution (1 mg/ml in PBS) was added to each well and 
incubated for 3h. Then the medium was carefully removed, and 100 µl of DMSO was 
added to each well. Plates were then put on a shaker for about 1 hour until all crystals 
were dissolved. Then the cell viabilities were determined by measuring the absorbance 
at 550 nm.  
 
Neutral red up take assay was carried out following the previous described protocol
168
; 
cells were seeded and treated in the same way as in MTT assay. Neutral red working 
solution (40 µg/ml in culture medium) was incubated overnight at the same temperature 
as the cells, and then centrifuged to remove any precipitated dye crystals. The treatment 
medium was then removed and 100 µl of neutral red medium were added into each 
well. The plate was incubated for 2 hours at the appropriate culture conditions. Then 
the neutral red medium was removed and the cells were washed with 150 µl PBS 
carefully. Then 150 µl neutral red destaining solution (50% ethanol 96%, 49% 
deionized water, 1% glacial acetic acid) was added into each well. The plate was then 
placed on a plate shaker until the neural red has been extracted from the cells. Then the 
cell viabilities were determined by measuring the absorbance at 540 nm. 
 
For trypan blue exclusion assay, after the treated cells were collected, cells were 
centrifuged and resuspended in PBS. The density of the cells was determined using a 
hemocytometer. Then in every 1 ml cell suspension, 0.1 ml of trypan blue stock 
solution (0.4% trypan blue in PBS) was added. The numbers of the blue staining cells 
were counted right away, and the cells which took up trypan blue were considered non-
viable. 
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3.1.4 Measuring TrxR activity using fluorescent method 
 
Insulin reduction assay and DTNB reduction assay are two most commonly used 
method to measure TrxR activity in purified protein or in cell lysates. But in order to 
detect TrxR activity in precious biological materials, such as cell lysates from different 
subcellular organelles, or cell samples containing a low amount of TrxR, a newly 
developed fluorescent method was applied in the studies
169
.  In the fluorescent method, 
insulin was replaced by isothiocyanate-labeled insulin (FiTC-insulin), which emits 
fluorescence at 520 nm after excitation at 480 nm. Upon the reduction of the disulfide 
by Trx, the fluorescence is increased. Compared to the conventional methods, 
fluorescence method is highly sensitive and stable
169
. 
 
Generally, in a 96-well black micro titer plates, appropriate amount of cell lysates were 
incubated with 20 µM of Trx and 0.25 mM NADPH in assay buffer (0.2mg/ml bovine 
serum albumin in 50 mM Tris-Cl and 1 mM EDTA, pH 7.5), the total volume was 90 
µl in each well. After incubation 30 min at 37°C, 10 µl of FiTC-insulin was added into 
each well. The final concentration of FiTC-insulin in each well is 10 µM. Then the 
emission at 520 nm after 480 nm excitation was recorded for 60 min in room 
temperature. The rate of the reaction was calculated as the changes of fluorescence 
following time. In paper IV, due to the very low amount of TrxR in SH-SH5Y cells, an 
improved fluorescent method was used, in which FiTC-insulin was replaced by a new 
fluorescent substrate from the latest developed kit (FkTRXR-03-Star) by IMCO 
(www.imcocorp.se). 
 
3.1.5 Redox Western Blot 
 
To determine the redox state of Trx1 in cells, the experiment was performed based on 
the method described previously
38,166
. Cells were washed three times in cold PBS and 
then lysed in urea lysis buffer containing iodoacetamide (IAM) (10 mM IAM, 50 mM 
Tris-HCL, 1mM EDTA, 8 M urea, and pH 8.3). Then the proteins were precipitated 
and washed three times to remove the excess IAM with 1.5 ml of ice-cold acetone/HCl 
(98/2, v/v). The precipitate was then resuspended in urea lysis buffer containing 3.5 
mM DTT to reduce the disulfides in Trx1. The free thiols of Trx were then alkylated 
with 30 mM iodoacetic acid (IAA) in urea lysis buffer. The samples were then 
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separated by PAGE containing 8 M urea and transferred with an Invitrogen transfer 
system. 
 
 
Figure 4. Principle of modified redox western blot (from paper II ) 
 
As exhibited in Fig. 4, in 8 M urea, proteins were all denatured and all the thiols were 
exposed. When first incubated with IAM, the free thiols in Trx1 were labeled with 
IAM, which will not give any extra charge to the protein. After removing excess IAM, 
the thiols which are oxidized into disulfide or bind to other proteins were reduced by 
3.5 mM DTT, and were labeled by IAA. IAA is negatively charged, so the protein 
labeled with more IAA will migrate faster in the urea gel. In the end, Trx1 can be 
separated according to the free thiols they contained initially.  
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3.2 RESULTS AND DISCUSSIONS 
 
3.2.1 Paper I 
Xu Zhang, Yujuan Zheng, Levi E. Fried, Yatao Du, Sergio J. Montano, Allie Sohn, 
Benjamin Lefkove, Lars Holmgren, Jack L. Arbiser, Arne Holmgren, Jun Lu. 
Disruption of the mitochondrial thioredoxin system as a cell death mechanism of 
cationic triphenylmethanes. Free Radical Biology & Medicine 50 (2011) 811-820. 
 
Trx2 system, comprising Trx2, TrxR2 and NADPH, catalyzes the disulfide reduction in 
mitochondrial matrix
25
. Prx3 is the main substrate of Trx2 in mitochondria, which can 
scavenge H2O2. In addition, Trx2 plays a key role in regulating mitochondria-
dependent apoptosis by binding to ASK1 and Txnip, as well as regulating the 
mitochondrial permeability transition
2,26–28,170
. However, compared to Trx1 system, 
which is found to be over-expressed in many cancer cells and merging as an anticancer 
therapeutic target
24,129
, the role of Trx2 system in cancer is less clear. 
 
Cationic triphenylmenthane dyes, have been used by human beings for more than a 
century as antifungal and antibacterial agents
171–173
. Recently, some of them have also 
shown potent anticancer activity in mice and humans
174
. However the exact mechanism 
of these dyes remains unclear.  
 
In this study, we found that Hela cells over expressing Trx2 in mitochondria compared 
to normal Fibroblast cells. Hela cells also showed to be more vulnerable upon BG treat 
compare to Fibroblasts. Down-regulation of Trx2 in Hela cells by siRNA technique 
resulted in a massive increase of cytotoxicity upon BG treatment, whereas, the same 
siRNA treatment in Fibroblast cells exhibited no significant change compared to 
untreated cells. These results suggest that the viability of Hela cells is more dependent 
on Trx2 than that of Fibroblasts. 
 
We then performed fluorescence staining to detect the subcellular location of BG. The 
treatment of BG resulted in green fluorescence, which was overlapping with the 
MitoTracker red mitochondrial staining. Furthermore, we investigated the cellular 
response upon BG treatment in Hela cells and in Fibroblasts. Both Hela and Fibroblast 
cells were treated with various concentrations of BG (0.25 to 2μM) for 24 hours. There 
was only a marginal increase in Trx1 and TrxR1 protein levels, but no significant 
effects on TrxR activity in cell lysates. Interestingly, Trx2 protein levels were 
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dramatically decreased upon the treatment with low concentrations of BG (0.25 to 1.0 
μM), both in Hela and in Fibroblast cells. Upon the treatment with 2 μM BG, the 
degradation of Trx2 was attenuated. RNR R1 protein level was not affected by BG 
treatment, whereas, RNR R2 protein, which is only expressed in S phase
175
, almost 
disappeared upon 1.0 μM and 2.0 μM BG treatment. We applied a redox western blot 
method, which can detect the redox state of all the thiols in Trx1 or Trx2, to analyze the 
redox state of Trx1 and Trx2 as a result of BG treatment. Without any treatment, most 
Trx1 and Trx2 were in the fully reduced form. Upon 24 hours BG treatment, the 
reduced form of Trx1 or Trx2 decreased dramatically. By isolation of different cell 
organelles, we detected that the loss of Trx2 resulted in translocation of cytochrome c 
from mitochondrial to cytosol and shuffling of Trx1 from cytosol to nucleus.  
 
In order to study how Trx2 is degraded upon treatment with BG, we used MG132, 
which is an inhibitor of both proteome and mitochondrial Lon protease, to treat Hela 
cells together with BG. The presence of MG132 can prevent the Trx2 degradation to 
some degree. We also found that upon the BG treatment, Lon protease mRNA was 
elevated. Thus we propose that mitochondrial Lon protease may mediate the Trx2 
degradation process. 
 
Discussion 
 
The Trx1 and Trx2 system locate and exert their specific functions in different 
subcellular compartments. Trx1 is mainly located in cytosol. Trx1 is an electron donor 
for RNR, which is the rate limiting enzyme in DNA synthesis
19
. In mitochondria, 
where Trx1 only locates in the inter-membrane space, Trx2 is the most important 
enzyme to keep the redox balance in the matrix. Trx2 can provide electrons to Prx3, 
which can in turn remove the excess of H2O2 produced by oxidative respiration. In our 
study, under oxidative stress conditions, Trx1 and Trx2 system responded differently. 
Upon oxidative stress, Trx1 was found to translocate from cytosol into nucleus, where 
it can exert its function as a regulator of some transcription factors, such as Nrf2
124
. 
Upon the treatment of BG, the mRNA level of Trx1 and TrxR1 was significantly 
increased, where as, the mRNA level of TrxR2 was changed moderately and the 
mRNA level of Trx2 was almost unchanged.  
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The cationic triphenylmethane used in this study dyes belong to the lipophilic cations, 
which can easily pass through the lipid bilayers. The mitochondrial membrane potential 
(150-180 mV) is much higher than the plasma membrane potential (30-60 mV). This 
difference between membrane potentials drives the dyes to move into and accumulate 
in mitochondrial matrix
176
. This property of the dyes allowed them to interact with the 
Trx2 system in mitochondria, whereas the Trx1 system in cytosol was not affected 
directly. A remarkable founding in this study is that Trx2 was oxidized and degraded 
after BG treatment. Though we did not find any inhibition on TrxR both in cytosol and 
in in mitochondria, a purified TrxR protein can be inhibited by BG in vitro by reacting 
with the active-site cysteine/selenocysteine.  
 
As a quality control enzyme, Lon protease has been found to be up-regulated under 
oxidative stress, and can specifically degrade oxidized proteins in mitochondria, such 
as aconitase
177,178
. Under the low concentration of BG treatment (below 1 μM), 
oxidized Trx2 will be degraded by Lon protease, however, when the concentration of 
BG treatment increased to above 2 μM, the degradation was diminished. This maybe 
because when Trx2 was highly oxidized, then it was unable to be degraded by Lon 
protease. The same property was also observed in the previous study, when aconitase 
was highly oxidized then it is difficult to be removed by Lon protease
177
. The existence 
of highly oxidized Trx2 in mitochondrial matrix will cause more dramatic cell death 
(above 2 μM treatment), compare to lower concentration treatment. This is also in line 
with the previous finding about the role of Lon protease in cell survival
179
. In addition, 
when over-oxidized Trx2 was not removed by Lon protease, the induction of HO-1 and 
NQO1 was also abolished.  
 
In summary, the results in this paper demonstrate that the viability of some tumor cells 
is more dependent on the Trx2 system than normal fibroblast cells. When 
mitochondrial Trx system was disrupted by triphenylmethane dyes such as brilliant 
green, Trx2 was oxidized and degraded by Lon protease. However, over-oxidized Trx2 
was not able to be removed by the cells. The results also shed light on the fact that 
mitochondrial Trx system can be a novel anticancer therapeutic target. 
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3.2.2 Paper II  
Yatao Du, Huihui Zhang, Xu Zhang, Jun Lu, Arne Holmgren. Thioredoxin 1 Is 
Inactivated Due to Oxidation Induced by Peroxiredoxin under Oxidative Stress and 
Reactivated by the Glutaredoxin System J. Biol. Chem. 2013, 288:32241-32247 
 
 
Hydrogen peroxide was long considered as only the by-product of respiratory chain and 
a major source of oxidative stress in cells. However, more and more studies have 
already proved the role of H2O2 as a second messenger in redox signaling
45,180
. Prxs can 
remove excess amount of H2O2 in living cells to protect cells from oxidative stress. On 
the other hand, Prxs may also be able to control the concentration of H2O2; the latter 
can exert its function as a signaling molecule
45
. By providing electrons to oxidized 
Prxs, Trx also plays important role in regulation of redox signaling. Trx1 with two 
disulfide (Cys32-Cys35, Cys62-Cys69) cannot be reduced by TrxR together with 
NADPH, and cannot provide electrons to Prxs anymore
96,181
.  
 
In our study, we found that in A549 cells, two-disulfide formed Trx1, with or without a 
thiol, can be found when cell were treated with a high dose of H2O2 (15 mM). In order 
to further investigate the formation of second disulfide (Cys62-Cys69), we prepared 
two types of Trx1: the active site double mutant Trx1 (SGPS) and Trx-S2, in which the 
active site cysteine residues was oxidized into disulfide by incubation with insulin. In 
both case, upon H2O2 treatment we can observe the formation of the second disulfide, 
but the present of Prx1 can strongly enhance the formation of the second disulfide. 
Ebselen is a substrate for both TrxR1 and Trx1, and it is a superfast oxidant for Trx1
182
. 
In Hela cells, the treatment of ebselen itself did not change the redox state of Trx1, 
however, upon the addition of BSO, Trx1 shifted into oxidized form dramatically. 
These results suggested that GSH system protected Trx1 from oxidation in cells. By 
using purified protein, we have found that GSH system can provide electrons and 
reduce two-disulfide form Trx1 (Trx1-S4) or Trx1 (SGPS)-S2. We also used E. coli 
Grx1C14S mutant to explore the mechanism of Grx system in reducing the non-active 
site disulfide of Trx1. Grx1C14S mutant also showed the capacity to reduce Trx 
(SGPS)-S2, which indicated that the reduction of non-active site disulfide by Grx1 
followed the monothiol mechanism.  
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Discussion 
 
Mammalian Trx1 has five cysteine residues, two of which locate in the active site 
(Cys32 and Cys35), and can reduce the disulfide in the target proteins. There are three 
so-called structural cysteines: Cys62, Cys69 and Cys73. Cys73 was known to be 
involved in the dimer formation, and Cys62 and Cys69 can form an extra disulfide, or 
so-called the second disulfide in Trx1. The formation of the second disulfide will affect 
its ability of reducing the disulfide in its substrates, as well as binding to its substrate 
such as ASK-1
103,183,184
. Trx1 with two disulfides was not a substrate of TrxR anymore, 
so it is important to investigate the regulation of the formation and reduction of the 
second disulfide. In our study, we found that GSH and Grx system can efficiently 
reduce Trx1 with two disulfide, which made the cycle of Trx1-(SH)5 to Trx-S4 is 
possible in living cells. Upon oxidative stress, Trx1 was oxidized into Trx-S4 form and 
the inactivation of Trx1 shuts down the electron flux from Trx1 to Prx1 to reduce H2O2, 
which may cause a transient increase of H2O2 amount, which in turn can exert its 
function as a secondary molecule. We also found that H2O2 alone was not very 
effective in terms of oxidizing Trx1. H2O2 was much more affinitive to Prx1 than to 
Trx1. Therefore, when the amount of H2O2 is enough, Prx1 will be oxidized and then it 
can oxidize Trx1 and give rise to formation of the second disulfide in Trx1. Similar 
mechanism was observed in endoplasmic reticulum (ER), where Prx4 can be oxidized 
by H2O2 and form a disulfide. Oxidized Prx4 can then transfer the disulfide to protein-
disulfide isomerase thiols for the folding of newly synthesized proteins
45,185,186
.  
 
As a signaling messenger, H2O2 exerts its function by oxidizing and temporally 
inhibiting the effectors, such as protein-tyrosine phosphatases and tumor suppressor 
PTEN
45,187
. Prxs can remove excess H2O2 and get oxidized. There is a hypothesis called 
“floodgate hypothesis” that oxidized Prxs act as a peroxide floodgate, keeping 
peroxides away from its targets until the floodgate has to be open
180,188
. The 
inactivation of Trx1 by forming the second disulfide provides the possibility to 
inactivate Prxs, thus plays an important role in the regulation of oxidative signals.  
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3.2.3 Paper III  
Huihui Zhang, Yatao Du, Xu Zhang, Jun Lu, and Arne Holmgren. Glutaredoxin 2 
Reduces Both Thioredoxin 2 and Thioredoxin 1 and Protects Cells from Apoptosis 
Induced by Auranofin and 4-Hydroxynonenal. Antioxidant & Redox Signaling. 2014 
Feb 4. Epub ahead of print 
 
The Trx system, composed of Trx, TrxR and NADPH, and the Grx system, composed 
of GSH, Grx, GR and NADPH, are two major thiol-disulfide oxidoreductases systems 
in mammalian cells. They play critical roles in maintaining cellular redox homeostasis, 
DNA synthesis and regulating redox signaling of cell survival/apoptosis
189–191
. In 
resting cells, the two system work parallel due to their different substrate groups. In 
general, Trxs are more active in catalyzing the disulfide exchange reaction with its 
protein substrates. For example, Trxs will provide electron for peroxiredoxins, which is 
the major player in scavenging H2O2
45
. Trxs can also regulate several transcript factors, 
such as NF-κB, Ref-1; and apoptosis signaling factor such as ASK-1124. Grxs, on the 
other hand, are specifically active in catalyzing the deglutathionylation of their protein 
substrates at the expense of GSH
189
. Grx2, mainly located in mitochondrial matrix, but 
was also found in the cytosol of testis and some specific cancer cell lines
138
. Grx2 
shares 34% sequence identity with Grx1, and has a higher affinity toward the S-
glutathionylated substrates, but with a lower turn over
141
. Moreover, Grx2 is not 
inactivated by oxidation, thus can be a great back up for Trxs or Grx1 under oxidative 
stress condition
192
.  
 
Previous studies have proved the existence of cross talks between Trx and Grx systems. 
For example, Grx2 can receive electrons from both GR and TrxR
141
, and Grx system 
can work as a backup for TrxR in cytosol and keep Trx1 in the reduced form even 
when TrxR1 was inhibited
166
. However, the backup system for Trx2 in mitochondrial 
matrix is still unclear. 
 
In this study, we found that GSH alone could reduce oxidized Trx1 and Trx2 in the 
present of NADPH and GR, by adding Grx2, can greatly accelerate the reaction in 
vitro. In order to prove that Grx2 can also reduce Trx1 and Trx2 in cells, we used Hela 
cells which can stably overexpressing Grx2 to do further experiments. Both WT and 
Grx2 overexpressing Hela cells were treated with various concentrations of auronofin 
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(AF) and 4-hydroxynonenal (HNE), the Grx2 overexpressing cells were much more 
resistant to both treatments. By using redox western blot, we found that the treatment of 
HNE in WT Hela cells resulted in almost fully oxidize of Trx2, whereas, in the Hela 
cells overexpress mitochondrial Grx2 (M-Grx2) or cytosolic Grx2(C-Grx2), most Trx2 
were still in the reduced form. The overexpression of M-Grx2 exhibited a better 
protection comparing to the overexpression of C-Grx2. Similarly, the overexpression of 
M-Grx2 and C-Grx2 produced the same positive effect in the protection of Trx1 from 
being oxidized by HNE treatment. On the contrary, the knockdown of Grx2 in Hela 
cells resulted in weakened cell viability upon AF or HNE treatment compare to WT 
Hela cells. The redox state of Trx1 and Trx2 showed an enhanced oxidation in Grx2 
knockdown cells after treatment by HNE. The activity of Grx2 is not affect by HNE. 
 
Discussion 
Both Trx1 and Trx2 are crucial for cell survival. The homozygous knockout of Trx1 or 
Trx2 mouse showed embryonic lethality
29,30
. Meanwhile, certain cell lines with 
homozygous knockout of TrxR1 or TrxR2 can still survival
193,194
. These finding 
suggest that there must be a backup system for Trx1 and Trx2 besides TrxRs. The 
depletion of GSH would cause cell death in TrxR2
-/-
 cells, implied the importance of 
GSH and Grx system as a backup system. In our study, we found that enzymatically, 
GSH can reduce the oxidized Trx1 or Trx2, but only when Grx2 was present, the 
reaction rate of Grx system as a backup is comparable to TrxR.  
 
Grx2, but not Grx1 can form dimers through an iron-sulfur cluster together with two 
molecules of noncovalently bound GSH between the active sites of Grx2 
monomer
139,140
. The Grx2 in dimmer form is not active as a reductase, however, upon 
oxidative stress, when the GSH pool became oxidized, the Grx2 dimer can be 
dissociated and catalytically active Grx2 will be released. Moreover, Grx2 is very 
resistant to oxidative stress compare to other thiol-based proteins
103
. Thus, under 
oxidative stress, when TrxR were inhibited, Grx2 can be a suitable backup.   
 
In summary, our study provides a new insight into the new role of Grx2 in 
antioxidative and anti-apoptotic functions, by catalyzing the reduction of oxidized Trx1 
and Trx2. In mammalian cells, both Trx system and Grx system are crucial for 
maintaining a reducing environment in cells and cell survival. In resting cells, these two 
systems work parallel, but under some circumstances, when TrxR was inhibited, Grx2 
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can catalyze the reduction of Trx1 or Trx2, thus, strengthens the cellular antioxidant 
capacity. 
 
 
 
3.2.4 Paper IV  
Xu Zhang, Jun Lu, Yatao Du, Panayiotis V. Ioannou and Arne Holmgren. Besides 
Inhibition of Thioredoxin Reductase, Oxidation of the Structural Cysteine residues in 
Thioredoxin by Certain Arsenicals Enhance Cytotoxicity to Cancer Cells. Manuscript 
 
Arsenic is a widely existing metalloid in soil, water and air. Acute exposure to arsenic 
may cause acute poisoning, and chronic exposure may cause several diseases including 
cancer
195
. Paradoxically, arsenic trioxide (ATO) was discovered as a treatment for 
acute promyelocytic leukemia in 1990s, and now many studies showed the possibility 
of using ATO to treat solid tumors
196,197
. ATO treatment will cause depletion of GSH 
and inhibition of TrxR in cancer cells
129,160,198
, and  thus can damage the redox balance 
in cancer cells.  
 
Trx1 has two cysteine residues in its active site (WCGPC), which can reduce the 
disulfide of target proteins by a thiol-disulfide exchange reaction. Besides, Trx1 also 
has three so called structural cysteines (Cys62, Cys69 and Cys73), and Cys62 and 
Cys69 can form an extra disulfide in Trx1. These additional cysteines caused more and 
more attentions, studies have shown that the disulfide between Cys62 and Cys69 is 
important for the regulation of Trx1 activity and its function in redox signaling
97,199
. 
 
In this study, we found that the structures of the arsenical compounds are closely linked 
to their ability to oxidize Trx1. Three out of eight compounds, which all have a 
resonance structure, have the ability of oxidizing Trx into dimer or higher oligomers. 
However, As5, which can oxidize Trx1 but lacks the ability of inhibit TrxR, cannot 
induce cytotoxicity in SH-SH5Y cells. Thus, the inhibition of TrxR is the basis of 
arsenic induced cell death. As6 and As7, on the other hand, can both inhibit TrxR and 
oxidize Trx, and exhibited the strongest cytotoxicity among all the arsenical 
compounds.  
 
To further investigate why As6 and As7 had greater cytotoxicity, a redox western blot, 
which can identify the redox state of each individual cysteine in Trxs, was applied. 
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Combining with the results from DTNB titration, we confirmed treatment with As7 
showed a gradually decreasing in the number of free thiols in Trx1 along the ratio 
between As compounds and TRx1 was increasing. The treatment of As6, on the other 
hand, can only cause two specific cysteine residues oxidized in Trx1. ATO showed no 
change of the number of free thiols in Trx1, even using as high as ten times of the 
concentration of Trx1. In order to determine the interaction between As6 and Trx 
thiols, we analyzed the redox state changes of Trx1, Trx2 and Cys62S/Cys73S double 
mutant after As6 treatment. The results showed that only the wtTrx1 can form a 
disulfide upon As6 treatment, which suggest the disulfide maybe formed between 
Cys62 and Cys69. 
 
We also looked into the cellular response upon As6 or As7 treatment. SH-SH5Y cells 
were treated with various concentration of As7 for 24 hours, there were no significant 
changes of Trx2 or TrxR1 amount in protein level, however, the amount of Trx1 was 
dramatically increased at 5 µM and above treatment. The redox western revealed that 
before any treatment, a large part of Trx1 was in fully reduced form, after 8 hours of 10 
µM As6 treatment and after 4 hours of 10 µM As7 treatment, the oxidized form of Trx1 
became obvious. There was also Trx1 with loss of four thiols present in As7 treatment, 
especially after 24 hours treatment. Our in vitro experiment using Prx1 as the substrate 
of Trx system showed the fact that only As6 and As7 treatment affect the ability of Trx 
system to reduce Prx1, whereas ATO treatment, which can inhibit the activity of TrxR, 
can only partially affected the capacity of Trx to reduce Prx1. 
 
Discussion 
 
TrxR is by far one of the most well understood selenoproteins. The selenocysteine is 
located in the open C-terminal active site of TrxR which makes it easy to be accessed; 
and its low pKa value makes it is highly reactive
200,201
. These characters make TrxR an 
easy target of many electrophilic compounds, such as mitomycin C, doxorubicin, and 
ATO as well
126,127,202
. In a previous study of our group, we found that ATO inhibits the 
C-terminal activity of TrxR, most likely by binding to the selenocysteine of TrxR. 
Studies have also shown that targeting the selenocysteine of TrxR can not only inhibit 
the activity of TrxR but can also turn TrxR into a NADPH oxidase and enhance ROS 
production in cells
128,203,204
.  
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There is accumulating evident showing that the structural cysteine residues, especially 
Cys62 and Cys69 which can form an extra-disulfide in Trx1, may play important roles 
in regulating Trx1’s function. Trx1 with 2-disulfide is not a substrate of TrxR anymore. 
Our recent study showed that the Trx1 with 2-disulfide can be reduced by Grx system, 
and we also found the existence of Trx1 with 2 disulfide in A549 cells treated with high 
dose of H2O2. In line with these studies, we have found that when Trx was oxidized 
into two-disulfide form, cell death happened massively. We have also discovered that 
oxidation of C62 and C69 into disulfide can affect Trx1’s ability of reducing Prx1. 
H2O2 is not only an oxidative stress molecule as the by-product of respiratory chain, but 
also an important signal molecule in redox signaling
46,180
. Thus, the inactivation of Prx1 
can cause a transient increase of H2O2, which make it is possible to induce oxidative 
stress dependent signals. Besides the ability of removing H2O2, Prx1 also plays 
important role in regulating cell death by interacting with the life span regulator protein 
p
66shc 205
. 
 
Cancer cells are found to be less tolerance to oxidative stress, most likely because they 
already have elevated ROS levels due to the impaired respiratory chain and defects in 
regulating of redox balance
122,123
. Cancer cells may prefer a moderate elevated ROS, 
because it can promote cancer cell growth and survival by activating a series of 
enzymes, such as MAPK, ERK and cyclin D1
27
. However, when extra ROS is induced 
in cancer cells, it can induce cell death through multiple pathways, such as activation of 
ASK1, release of cytochrome c from mitochondria and p53 induction, etc
27,124,125,206
. 
Trx1 and TrxR as anti-oxidative stress enzymes were found to be overexpressed in 
many cancer cell lines. But SH-SH5Y cells are one of the a few cancer cells which 
have lower expression of Trx1 and TrxR compare to other cancer cells and normal 
fibroblast cells. In line with its nature, the cellular environment of SH-SH5Y cells is 
more oxidized compare to Hela or A549 cells
97,206
, because even in untreated cells, the 
Trx1 is not fully reduced. This property may make Trx system in SH-SH5Y cells is a 
more effective target for anticancer therapeutic treatment. 
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3.2.5 Paper V  
Manuel M. Paz, Xu Zhang, Jun Lu, and Arne Holmgren. A New Mechanism of Action 
for the Anticancer Drug Mitomycin C: Mechanism-Based Inhibition of Thioredoxin 
Reductase. Chemical Research in Toxicology. 2012 Jul 16; 25(7):1502-11 
 
Mitomycin C (MMC) has been used in combination chemotherapy since 1974, and has 
been used as an antibiotic for several surgical procedures
127,207,208
. The anticancer 
mechanism of MMC has been focused on its ability to bind covalently to DNA
207
. 
Recently, the hypothesis that MMC can induce redox cycling and increase ROS level in 
tumor cells has arose
209
. The protype of MMC is inert toward nucleophiles, but upon 
bioreduction, it became very reactive bis-electrophiles
210
. However, the exact 
mechanism of how MMC is reduced in cells is not clear. In recent studies, GRP58, a 
protein that containing thioredoxin-like domains, was proposed to be able to reduce 
MMC into its active form
211
. Studies have also shown that simple dithiols, such as 
DTT, could activate MMC by reduction. The activated MMC would then bind to the 
two sulfur atoms of the dithiol
212
. So we proposed that MMC could also act as an 
inhibitor of enzymes containing a dithiol active site.  
 
In our study, we have observed that TrxR was irreversibly inactivated by MMC, and 
the inhibition is both time and concentration dependent, but not pH-dependent. 
NADPH is required for the inhibition, which suggested that the inhibition involved the 
reduced form of the C-terminal active site of TrxR. But incubating MMC, TrxR and 
NADPH together would not cause consumption of NADPH, and no metabolites of 
MMC were found after the incubation, so MMC is not a substrate of TrxR. Addition of 
ethyl xanthante as external nucleophile did not influence the inhibition, suggested that 
MMC inactivated TrxR by binding to the active site. By using UV spectroscopy we can 
also characterize the complex of TrxR-MMC. By comparing the difference between 
unmodified TrxR and MMC inactivated TrxR, the spectrum of the mitosene derived 
from reductively activated MMC was shown.  
 
We have also studied the toxic effect of MMC in different cell lines: Du145, Hela, 
A549 and MCF7, among all the cell lines, human prostate cancer cell Du146 cells were 
the most sensitive to the MMC treatment. MMC could inhibit TrxR in cells, and the 
loss of TrxR activity was consistent with the loss of cell viability. The cellular response 
of Trx system was also analyzed upon MMC treatment, and there was only a slight 
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decrease in the level of TrxR, so the loss of the TrxR activity was most likely due to the 
inhibition of TrxR by MMC but not the loss of TrxR at protein level.  
 
Discussion 
 
In the end, we proposed that MMC is a mechanism based inhibitor of TrxR because the 
inhibition fulfilled the requirements by which an inhibitor can be classified as a 
mechanism based inhibitor, as known as suicide inhibitor. The requirements are: a.) 
Time and concentration dependent; b.) irreversible; and c.) active-site directed, and d.) 
the conversion of enzyme-bound inhibitor to an active form. The exact mechanism was 
presented in scheme 1. 
 
Scheme 1. Proposed mechanism for the mechanism based inhibition of TrxR by MMC 
(Paper V) 
 
First, the selenolate from the Sec-498 of TrxR can form a conjugate to the quinone ring 
of the MMC to form a covalent complex intermediate (8). Then the intermediate 
undergoes an internal redox reaction involving the transfer of electron from Cys-497 to 
MMC to form a noncovalent complex 9. Then the hydroquinone of MMC (9) will 
undergoes a series of reactions (9,10,11,12) to generate the active intermediate. The 
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activated MMC can then react with the reduced C-terminal active site seleoate of TrxR 
when NADPH is present. (13 – 19) 
 
The biological mechanism of action of MMC has mainly focused on its ability of 
crosslinking complementary strands of DNA
213
 ever since it was first investigated in 
the 1960s. Considering the fact that bioactivitied MMC is highly reactive, other type of 
targets may exist. Recently, ribosome RNA was also found as a target of MMC
214
. In 
our study, we found that TrxR is strongly inhibited by MMC both in vitro and in cells 
suggest TrxR is a cellular target for MMC as well. TrxR is known as an emerging 
anticancer therapeutic target, and plays important roles in cancer development and 
progression
21,24,215,216
. TrxR was already known as a target of some other DNA 
alkylating agents such as: cisplatin, doxorubicin and ifosfamide
217–219
. Our finding 
support the ability of TrxR as a target for anticancer drugs, and MMC may function as 
a multi-target drugs. 
 
3.2.6 Paper VI  
Cristina M. L. Carvahlo, Jun Lu, Xu Zhang, Elias S. J. Arner, and Arne Holmgren.  
Effects of selenite and chelating agents on Mammalian thioredoxin reductase inhibited 
by mercury: implications for treatment of mercury poisoning. The FASEB Journal 2011 
Jan: 25(1):370-81 
 
Mercury is the only metal which is in liquid form and can evaporate in room 
temperature. Mercury toxicity induces damages in brain, kidney and immune system. 
Nowadays, people exposure to mercury mainly through the consumption of fish, the 
use of dental fillings containing mercury, and some vaccines with mercury compound 
as preservative, and acute exposure to mercury due to occupational reasons still 
happens
220,221
. Although the toxicity of mercury has been a highly interesting topic with 
a long history, the mechanisms of its toxicity and treatment were still not clear. 
 
Selenium is an essential trace element for human, and one important use of selenium is 
the synthesis of selenoproteins. Deficiency of selenium in dietary up take can result in 
loss of immune function, weakened reproduction, depression and cardiovascular 
diseases
117
. Although the interaction of selenium with mercury has been extensively 
reported since it was first reported by Parizek and Ostadalova in 1967
222,223
. The exact 
mechanism is still unclear. 
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In our study, we have found that TrxR is a target of mercury, both organic MeHg and 
inorganic HgCl2 can inhibit TrxR activity, but the inorganic form of mercury is more 
efficient. The presence of NADPH can largely enhance the inhibitory effect of both 
MeHg and HgCl2, which suggested that the active site thiol and selenothiol of TrxR are 
involved in the binding. GSH, on the other hand, showed a protection effect in both the 
treatments with MeHg and HgCl2, which is consistent with the previous finding that 
GSH can form complexes with both organic and inorganic mercury. 
 
In order to further invest the interaction of mercury with TrxR, we used mass 
spectrometry method to compare the mass change of treated TrxR with untreated TrxR. 
Table 3 showed the interpretation of the mas spectrum result. Both the treatment of 
MeHg and HgCl2 caused congregation of Hg with TrxR with maximum 8 Hg detected 
in 1 TrxR. Monovalent and bivalent mercury are both potent electrophiles, in our study, 
Hg
2+
 can bind to TrxR and damage its activity more effectively, whereas, the binding of 
MeHg showed less tendency of damaging its activity. Furthermore, in order to verify if 
selenocysteins in the C terminal active site of TrxR was involved in the binding of 
mercury, we used BIAM labeling method to detect the remaining Sec residue in TrxR 
after incubation with HgCl2 and MeHg. Both the treatment of HgCl2 and MeHg can 
cause the loss of detectable Sec residue in TrxR, but for HgCl2, a ratio to TrxR of 4:1 
can completely shelter the Sec residue; while for MeHg, the ratio needed to increase to 
8:1 in order to get the same effect.  
 
Table 3. MS analysis of HgCl2 and MeHg binding with TrxR. ( from Paper VI) 
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Because selenite is also the substrate of TrxR, so we tried to use selenite to measure the 
activity of TrxR after mercury treatment. To our surprise, with the selenite reduction 
assay, the activity of TrxR after MeHg treatment gave similar result as we observed in 
insulin reduction assay, while the activity of TrxR after HgCl2 treatment was 100% 
recovered even when NADPH was in presence. Then we confirmed this result by using 
insulin reduction assay to make sure that selenite can recovery the activity of TrxR 
inhibited by HgCl2. To further investigate the mechanism of the recovery, we 
performed mass spectrometry method to analyze the change of mercury biding to TrxR 
upon selenite addition. The result showed that selenite treatment resulted in new peaks, 
which coexist with the peaks appeared upon mercury treatment. These results 
suggested that the product of selenite reduction by TrxR, selenide, can remove Hg from 
the active site of TrxR. We have also compared the ability of reactivating TrxR by 
selenite with some clinical used chelating agents, such as BAL, DMPS and ALA. 
Selenite was as effective as any above mentioned chelating agents.  
 
We have also examined the recovery effect of selenite in cultured HEK293t cells, 
consistent with in vitro data; selenite was able to remove both the inhibition of TrxR 
activity and the cytotoxicity caused by HgCl2, but only at a relatively lower 
concentration (5 µM) and a shorter treatment time (9h). When the concentration of 
HgCl2 was higher than 10 µM, or the treatment was longer than 24h, then the 
protection effect of selenite was abolished.   
 
Discussion 
 
There are in total 14 cysteine residues and 1 selenocysteine in human TrxR: Cys59 and 
Cys64 locate in the N-terminal active site; Cys497 and Sec498 locate in the C-terminal 
active site, and the rest 11 cysteine residue which are not directly involved in the 
activity of TrxR, but some of which expose in the surface of the enzyme and are also 
able to bind with mercury. This may explain in the MS results we can observe as many 
as 8 mercury molecules binding to one TrxR, while titration with HgCl2, when NADPH 
was presence, a ratio between HgCl2:TrxR was 2, was enough to block almost 100% of 
the activity.  
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Scheme 2 demonstrated the proposed mechanism for the inhibition of TrxR by mercury 
and reactivation of it by selenium. Briefly, bivalent mercury compound (HgCl2) can 
target the reduced C terminal active site of TrxR, and binds to it to abolish its activity. 
Selenite can substitute the mercury molecule binds to the active site, and regenerate 
TrxR’s activity. 
 
 
Scheme 2. Schematic of the proposed mechanism for TrxR inactivation by mercury and 
reactivation by selenite. (from Paper VI) 
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3.3 CONCLUSION AND FUTURE PERSPECTIVES 
 
In our first paper, we showed that the degradation of Trx2 upon BG treatment. Through 
comparing with fibroblast cells, we demonstrate the importance of Trx2 in cancer cells, 
such as Hela cells. However, the exact interaction of BG and Trx2 is not clear. 
Although we have in vitro data showed that BG can binds to thiols in small molecule 
such as dithiothreitol (DTT), but we did not find direct evidence of BG binding to Trx1 
or Trx2 (unpublished data).  In addition, we also found that BG is a strong inhibitor of 
TrxR1 in vitro, although we cannot find the inhibition effect on TrxR in cell lysates, 
this maybe because BG specifically accumulated in mitochondrial matrix, where it can 
only inhibit TrxR2. But even only considering mitochondria, where TrxR2 locates in 
the matrix and TrxR1 locates in the inter membrane space; the amount of TrxR2 is still 
much lower than that of TrxR1. So it is very difficult to obtain the data on TrxR2 in 
cells. However, the interaction of BG with Trx2 system should be further studied 
because it is very important for the investigation of the mechanism of degradation of 
Trx2. We have proposed mitochondrial Lon protease to be responsible for the 
degradation of Trx2, but this need to be further confirmed as well. 
 
In paper II and IV, we investigated the importance of the second disulfide in regulating 
Trx1’s activity and functions. In paper II, we proposed that when Trx1 with two 
disulfides cannot be reduced by TrxR, Grx system can reduce it through a monothiol 
mechanism. In paper IV, we further demonstrated that the formation of the second 
disulfide in Trx1 can sensitize SH-SH5Y cells towards cytotoxicity induced by some 
arsenical compounds. In addition, in vitro data showed that the formation of the second 
compounds can weaken Trx1’s ability to reduce oxidized Prx1. However, because 
previous studies about Trx1’s activity and functions were almost all focused on the 
active site Cys residues of Trx1, the data about the functions of the second disulfide in 
Trx1 is very limited. Although we have found that Trx1 with two disulfides can be 
generated in A549 cells under high dose of H2O2 treatment, there is no data showing its 
existence under physiological conditions. In my opinion, physiological process 
involving a high dose of oxidative stress should be paid more attention to, such as 
during inflammation. In addition, since Trx1 with two disulfides is not a substrate of 
TrxR, then the delay of reducing it may give a chance of transient inhibition of Prx1, 
and causes an increase of H2O2, which can subsequently exerts its function as a 
signaling molecule. Although there is no doubt that H2O2 is a messenger molecule more 
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than just an evil oxidant. Considering that it can diffuse freely in the cells, the 
mechanism how it can exert its function locally without spread the signal all over the 
cells is still not clear. In our Paper III, we investigated the role of Grx2 as a backup of 
TrxR, which can reduce both the oxidized Trx1 and Trx2 in vitro and in cells when 
TrxR is inhibited. It is interesting to think about the fact that Grx2 is more resistant to 
oxidative stress compare to Grx1, and it actually can be activated by ROS. This finding 
proposed a possibility that under some oxidative conditions, Grx2, not Grx1 reduces 
Trx1 with two disulfides. Considering the fact that the amount of Grx2 is low and its 
subcellular locations, maybe it plays a role in regulating the amount of H2O2 locally. 
Another factor that needs to be considered is GSH, because both Grx1 and Grx2 need 
the expense of GSH to reduce Trx, and the amount of GSH various in different cell 
organelles. On all accounts, the regulation and mechanism of the whole signaling 
pathway (Grx1/Grx2Trx1Prx1H2O2) is not clear, more efforts should be spent 
on it, especially in a cellular model.  
 
In our last two papers, we demonstrated TrxR as a cellular target of anticancer drug 
mitomycin C and the toxic compounds of mercury, and that selenium can act as a 
detoxification compound of mercury toxicity with a comparable recovery capacity of 
clinically used chelating agents. It is not surprising that the exposed highly reactive Sec 
residue in TrxR is a target of several electrophilic compounds and metals. However, by 
collaborating with experts who works in the chemical field and toxicology field, 
brought us new tools and different angels to study the interactions of compounds with 
Trx system, which can be applied in future studies.  
 
In the end, it is worth to mention two new techniques which are developed and / or 
optimized by my colleagues during my PhD study, one is measuring TrxR/Trx activity 
by using fluorescent substrate, and another one is redox western blot. The new 
fluorescent method, which is very sensitive and stable, made it possible to measure the 
activity of TrxR/Trx in a very limited amount of cell samples, such as mitochondrial 
lysate; or cells with very low amount of TrxR/Trx, such as SH-SH5Y cells. The redox 
western blot made it is possible and reliable to analyze the redox state of each Cys 
residues in Trx1, thus it is a great tool to study the function of the structural Cys 
residues in Trx1. Moreover, it is possible to optimize the method and analyze the redox 
state of bigger molecules, such as peroxiredoxins. These two powerful tools will be 
applied more often in my future studies. 
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